Mylonakis Mathios E, Koutinas Alex F, Leontides Leonidas S
Clinic of Companion Animal Medicine, School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Vet Clin Pathol. 2006 Sep;35(3):311-4. doi: 10.1111/j.1939-165x.2006.tb00137.x.
Bone marrow mastocytosis has been reported rarely in naturally occurring canine monocytic ehrlichiosis (CME).
The aims of the present study were to estimate the prevalence and magnitude of bone marrow mastocytosis in a case series of dogs with natural CME and to assess the association, if any, between mastocytosis and the clinical severity of the disease.
Seventy-six dogs with confirmed CME (Ehrlichia canis) were included in the study. Affected dogs were allocated into group A (n = 51) without bone marrow hypoplasia and group B (n = 25) with bone marrow hypoplasia. Twenty clinically healthy Beagles not previously exposed to E canis served as controls (group C). The main inclusion criteria for group A were documentation of normocellular to hypercellular bone marrow and complete clinical cure following a 4-week treatment with doxycycline, while those for group B were bone marrow hypoplasia and lack of response to doxycycline. Bone marrow aspirate smears from all 96 dogs were Giemsa-stained and examined for the presence of mast cells, which were calculated as a percentage of 1,000 nucleated cells (NCs). The prevalence of mastocytosis was compared among the 3 groups by the Pearson's chi-square test.
Bone marrow mastocytosis (>0.1% of NCs) was found in 5 (20%) dogs in group B (range, 0.5-2.5% of NCs; median, 1% of NCs). One dog in each of groups A and C had 0.1% mast cells in the marrow. The prevalence of bone marrow mastocytosis in dogs in group B was significantly higher (P = .004) than in groups A and C.
Bone marrow mastocytosis can be seen in a substantial number of dogs with E canis-induced myelosuppression.
骨髓肥大细胞增多症在自然发生的犬单核细胞埃立希体病（CME）中鲜有报道。
本研究旨在评估自然感染CME的犬病例系列中骨髓肥大细胞增多症的患病率和严重程度，并评估肥大细胞增多症与疾病临床严重程度之间的关联（如有）。
76只确诊为CME（犬埃立希体）的犬纳入本研究。患病犬被分为A组（n = 51），无骨髓发育不全；B组（n = 25），有骨髓发育不全。20只先前未接触过犬埃立希体的临床健康比格犬作为对照（C组）。A组的主要纳入标准是骨髓细胞数量正常至高细胞数量的记录以及用强力霉素治疗4周后临床完全治愈，而B组的主要纳入标准是骨髓发育不全且对强力霉素无反应。对所有96只犬的骨髓穿刺涂片进行吉姆萨染色，并检查肥大细胞的存在情况，肥大细胞数量按每1000个有核细胞（NCs）的百分比计算。采用Pearson卡方检验比较三组肥大细胞增多症的患病率。
B组5只（20%）犬发现骨髓肥大细胞增多症（>0.1%的NCs）（范围为0.第5 - 2.5%的NCs；中位数为1%的NCs）。A组和C组各有1只犬骨髓中肥大细胞为0.1%。B组犬骨髓肥大细胞增多症的患病率显著高于A组和C组（P = 0.004）。
在大量犬埃立希体引起骨髓抑制的犬中可观察到骨髓肥大细胞增多症。
